E&G Advisors, LP Biogen Inc. Transaction History

E&G Advisors, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 12, 2021	SELL	$259.0 - $414.71 $271,950 - $435,445	-1,050 Closed	0 $0
Q1 2020 Apr 08, 2020	SELL	$268.85 - $341.04 $26,885 - $34,104	-100 Reduced 8.7%	1,050 $332,000
Q4 2019 Jan 10, 2020	SELL	$220.06 - $304.07 $3,300 - $4,561	-15 Reduced 1.29%	1,150 $341,000
Q2 2019 Jul 12, 2019	SELL	$219.29 - $241.72 $3,289 - $3,625	-15 Reduced 1.27%	1,165 $272,000
Q1 2019 Apr 18, 2019	SELL	$216.71 - $338.96 $253,550 - $396,583	-1,170 Reduced 49.79%	1,180 $279,000
Q4 2018 Jan 17, 2019	BUY	$278.5 - $352.75 $111,400 - $141,100	400 Added 20.51%	2,350 $707,000
Q3 2018 Oct 10, 2018	SELL	$293.51 - $383.83 $205,457 - $268,681	-700 Reduced 26.42%	1,950 $689,000
Q2 2018 Jul 30, 2018	BUY	$257.52 - $306.91 $283,272 - $337,601	1,100 Added 70.97%	2,650 $769,000
Q4 2017 Jan 16, 2018	SELL	$307.64 - $344.58 $175,354 - $196,410	-570 Reduced 26.89%	1,550 $494,000
Q3 2017 Oct 20, 2017	BUY	$281.15 - $329.69 $596,038 - $698,942	2,120	2,120 $664,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of E&G Advisors, LP, based on Form 13F filings with the SEC.

Stay updated on E&G Advisors, LP with notifications on news.